NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Verdiva Bio

Verdiva Bio

Private
GuildfordHealthcare & Life Scienceshttps://verdivabio.com/

Last Round

Series A

Jan 9, 2025

Total Funding Raised

$411M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Verdiva Bio is a biopharmaceutical company that develops next-generation oral and injectable therapies for obesity, cardiometabolic disorders, and related complications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

obesity treatmentoral GLP-1weight loss drugsGLP-1 receptor agonistGLP-1 drugsweight loss pillamylin agonistcardiometabolic therapiesclinical-stage biotechdrug in-licensingweight loss maintenanceoral peptide

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Verdiva Bio Comparables

Compare Verdiva Bio with similar companies based on industry and business-model similarity.

Verdiva Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pfizer
85%
Alveus Therapeutics
82%
Kailera Therapeutics
81%

Verdiva Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 9, 2025

Key People

Founding team and executive leadership

Tapan Maniar

Chief Business Officer Co-Founder

Founding Team

Khurem F.

Chief Executive Officer

Executive Team

Ashley Taylor

Chief Technology Officer

Executive Team

Verdiva Bio Investors

Notable investors and investment history

Verdiva Bio investors
InvestorRounds
Forbion Capital PartnersSeries A
RA Capital ManagementSeries A
ForbionSeries A
LYFE CapitalSeries A
OrbiMedSeries A
Logos CapitalSeries A
Lilly Asia VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 24, 2026

    Grew 17% QoQ, from 64 to 75 employees.

  • Apr 25, 2026

    Grew 25% QoQ, from 59 to 74 employees.

Verdiva Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Verdiva Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Verdiva Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersGuildford
Employee Range77
Year Founded2024
Last FundingJan 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.